Browse studies

Find your next paid study

1,849 recruiting studies matching your filters

AN INTERVENTIONAL, OPEN-LABEL, PHASE 2 STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY OR IN COMBINATION IN ADULT PARTICIPANTS WITH EARLY-STAGE RESECTABLE OR LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER

This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well it works when given alone or with c…

CarcinomaNon-Small-Cell LungLung Cancer (NSCLC)+6 more

National Liver Cancer Screening Trial

The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients…

Carcinoma, HepatocellularLiver CancerLiver Cirrhosis+1 more

Estimated

~$10 – $6,250

University of Texas Southwestern Medical CenterNCT06084234

Phase 2

A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-li…

CachexiaMetastatic Pancreatic Ductal Adenocarcinoma

A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination With Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer

The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (…

Carcinoma, Non-Small-Cell Lung

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT07586202

Phase 3

Investigation of Mitomycin C PIPAC - FOLFIRI Combination for Unresectable Appendiceal or Colorectal Peritoneal Metastases Treatment (IMPACT): A Multicenter, Randomized, Open-Label, Phase 3 Trial

This phase III trial studies how well pressurized intraperitoneal aerosolized chemotherapy (PIPAC) with mitomycin works versus (vs) standard chemotherapy (leuc…

Metastatic Appendix CarcinomaMetastatic Colorectal CarcinomaMetastatic Malignant Neoplasm in the Peritoneum+3 more

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT07271355

Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have…

Adenocarcinoma (NOS)Anal CancerBladder Cancer+24 more

Estimated

~$10 – $1,125

AstraZenecaNCT07124000

Phase 2

MC231007 Fucoidan For Patients With Chemotherapy-Related Fatigue: A Double-Blind, Randomized, Placebo-Controlled Pilot Study

This phase II trial tests how well fucoidan works in preventing chemotherapy-related fatigue compared to a placebo in patients with gastrointestinal (GI), gyne…

Malignant Digestive System NeoplasmMalignant Female Reproductive System NeoplasmBreast Carcinoma+2 more

Estimated

~$10 – $6,250

Mayo ClinicNCT06855524

Phase 2

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamo…

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+22 more

Phase 1

A Pilot Study of HIF-Mediated Gene Expression Changes in Casdatifan-Treated Refractory Renal Cell Carcinoma

This is a single-institution, pilot study of oral casdatifan, a selective HIF-2α inhibitor, in patients with metastatic clear cell renal cell carcinoma refract…

Refractory Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell Carcinoma

Estimated

~$10 – $6,250

Vanderbilt-Ingram Cancer CenterNCT07748988

Phase 3

A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants With Advanced RCC Who Have Progressed on or After Both PD-1/L1 and VEGF-TKI Therapies in Sequence or in Combination (LITESPARK-034)

Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a s…

Carcinoma, Renal Cell

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT07489495

Phase 1

A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC)

This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cance…

Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)

Estimated

~$10 – $8,750

Acerand Therapeutics (Hong Kong) LimitedNCT06801236

Observational

Efforts to Enhance Germline Genetic Testing at Lyndon B. Johnson Hospital

This clinical trial identifies factors associated with completing genetic testing, aids in the development of a decision support tool, and tests how well the d…

Prostate Carcinoma

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07377006